Compare HTZ & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTZ | NBTX |
|---|---|---|
| Founded | 1918 | 2003 |
| Country | United States | France |
| Employees | 26000 | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2018 |
| Metric | HTZ | NBTX |
|---|---|---|
| Price | $4.75 | $31.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $4.93 | ★ $26.00 |
| AVG Volume (30 Days) | ★ 5.2M | 49.3K |
| Earning Date | 05-11-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.97 | N/A |
| Revenue Next Year | $3.67 | $11.73 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.50 | $2.99 |
| 52 Week High | $9.39 | $41.89 |
| Indicator | HTZ | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.03 | 52.10 |
| Support Level | $3.78 | $20.11 |
| Resistance Level | $5.47 | $41.89 |
| Average True Range (ATR) | 0.26 | 2.20 |
| MACD | 0.09 | -0.72 |
| Stochastic Oscillator | 72.79 | 20.75 |
Hertz Global Holdings Inc is engaged principally in the business of renting vehicles through its Hertz, Dollar and Thrifty brands. The company has two reportable segments: i) Americas RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in the U.S., Canada, Latin America and the Caribbean, ii) International RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in locations other than the U.S., Canada, Latin America and the Caribbean. The company maintains a substantial network of company-operated rental locations, a majority of which are in Europe, and has franchisees and partners that operate rental locations under brands. Geographical markets include North America, Europe, Pacific Asia, Middle East and Africa, and Latin America.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.